Down 15%, is the Worldwide Healthcare Trust share price a bargain?

The Worldwide Healthcare Trust share price has been falling over the past year. Christopher Ruane considers whether he ought to buy.

| More on:

The content of this article was relevant at the time of publishing. Circumstances change continuously and caution should therefore be exercised when relying upon any content contained within this article.

A GlaxoSmithKline scientist uses a microscope

Image: GlaxoSmithKline

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More.

RISK WARNING: should you invest, the value of your investment may rise or fall and your capital is at risk. Before investing, your individual circumstances should be assessed. Consider taking independent financial advice. The Motley Fool believes in building wealth through long-term investing and so we do not promote or encourage high-risk activities including day trading, CFDs, spread betting, cryptocurrencies, and forex. Where we promote an affiliate partner’s brokerage products, these are focused on the trading of readily releasable securities.

Although healthcare is a big investment theme these days, it has not been a rewarding one lately for shareholders in Worldwide Healthcare Trust (LSE: WWH). The Worldwide Healthcare Trust share price has fallen 15% in the past year. Could that make this an attractive moment for me to add the company to my portfolio?

Why I like the idea of a healthcare investment trust

Healthcare is an area where I expect to see resilient and indeed growing demand in the long term. When it comes to taking care of their health, many people are willing to spend a lot of money if they have it. So the area can be lucrative.

But without medical expertise myself, it can be hard to assess the attractiveness of some healthcare shares. That is why an investment trust appeals to me, as I can hopefully benefit from a diversified range of investments chosen by a professional manager.

Looking down the list of Worldwide Healthcare’s five biggest holdings at the end of July, I see such familiar names as AstraZeneca, Bristol-Myers Squibb, Humana, and Roche. A lot of the trust’s focus is on pharma companies and healthcare suppliers. So by investing in a trust like this, I ought to be able to get diversified exposure to the healthcare sector.

The Worldwide Healthcare Trust share price has fallen

However, although I like the idea of buying shares in a healthcare-focussed investment trust, is this the right one for me? After all, the recent share price performance has been weak and the dividend yield is below 1%.

Over the past five years, the performance looks better. The Worldwide Healthcare Trust share price moved up by 26% in that period. That is a decent gain in my view, though not remarkable. During that timeframe, for example, AstraZeneca has moved up 119%. But investing in one share would not have given me the diversification of an investment trust. AstraZeneca has done well in recent years, but some of its competitors performed far worse.

The long-term trend for the shares has been positive, although some years have seen better performance than others. In 2019, for example, the Worldwide Healthcare Trust share price saw a 32% jump. So although I do not expect this investment trust will ever match the performance of the best individual healthcare shares, I am hopeful it could give me a balance of diversified healthcare exposure and long-term growth.

My move

I would like to get some exposure to the healthcare sector for the long term. I see some advantages to doing that by buying shares in an investment trust. At the end of July, this particular trust was trading at a discount to its net asset value of less than 3%. Many pharma shares have what I regard as high price-to-earnings ratios right now. So I do not see the Worldwide Healthcare Trust share price as a bargain. It basically looks fairly priced for what it is to me.

But I would still consider investing some of my money in its shares as a way to participate in what I see as the long-term growth prospects of the healthcare sector.

RISK WARNING: should you invest, the value of your investment may rise or fall and your capital is at risk. Before investing, your individual circumstances should be assessed. Consider taking independent financial advice. The Motley Fool believes in building wealth through long-term investing and so we do not promote or encourage high-risk activities including day trading, CFDs, spread betting, cryptocurrencies, and forex. Where we promote an affiliate partner’s brokerage products, these are focused on the trading of readily releasable securities.

C Ruane has no position in any of the shares mentioned. The Motley Fool UK has no position in any of the shares mentioned. Views expressed on the companies mentioned in this article are those of the writer and therefore may differ from the official recommendations we make in our subscription services such as Share Advisor, Hidden Winners and Pro. Here at The Motley Fool we believe that considering a diverse range of insights makes us better investors.

More on Investing Articles

Investing Articles

Publish Test

Lorem ipsum dolor sit amet, consectetur adipiscing elit. Sed do eiusmod tempor incididunt ut labore et dolore magna aliqua. Ut…

Read more »

Investing Articles

JP P-Press Update Test

Read more »

Investing Articles

JP Test as Author

Test content.

Read more »

Investing Articles

KM Test Post 2

Read more »

Investing Articles

JP Test PP Status

Test content. Test headline

Read more »

Investing Articles

KM Test Post

This is my content.

Read more »

Investing Articles

JP Tag Test

Read more »

Investing Articles

Testing testing one two three

Sample paragraph here, testing, test duplicate

Read more »